This is a working overview of nuclear receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-28. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
==== Defence procurement ==== The Defence budget was protected by a NATO commitment to increase defence spending by 3% per annum until 1986, but was still subjected to cuts in the proposed budget during Heseltine's tenure. Some senior military figures felt that Heseltine was obsessed with the minutiae of running the department rather than thinking strategically about defence priorities and procurement. Dwin Bramall recalled that Heseltine never showed an interest in the strategy papers he sent him. Thatcher was highly critical of him for failing to take a decision on the development of the Nimrod early-warning plane, on which £660 million was spent over a ten-year period, only for the project to be cancelled by his successor. Some accusations were raised (the Commons Select Committee on Defence thought him "vague and evasive" on the issue in 1985) that the accounts were being massaged to push costs into the period after 1986, when cuts would become inevitable. The journalist Hugo Young later recalled Heseltine briefing journalists confidentially that spending and funding could be reconciled until 1986, by which time he expected "to be gone". In Cabinet, Heseltine resented being kept out of economic debates and suspected he might be reshuffled to the job of Secretary of State for Northern Ireland as Jim Prior had been. He had tried to pursue a one-man industrial policy, as defence spent £17 billion per annum, 5% of UK GDP, half of it on procurement, and 90% of that in the UK, with 700,000 British jobs dependent on it.
Eukaryotic protein kinases are enzymes that belong to a very extensive family of proteins that share a conserved catalytic core. The structures of over 280 human protein kinases have been determined. There are a number of conserved regions in the catalytic domain of protein kinases. In the N-terminal extremity of the catalytic domain there is a glycine-rich stretch of residues in the vicinity of a lysine amino acid, which has been shown to be involved in ATP binding. In the central part of the catalytic domain, there is a conserved aspartic acid, which is important for the catalytic activity of the enzyme.
== Background and recording == Produced by Ethan Kath, III was recorded in Berlin and Warsaw, and mixed in London. The album addresses the theme of oppression, with the musicians using different pedals and keyboards to create a diverse "palette of sound". "A lot of bad things have happened to people close to me since II and it's profoundly influenced my writing as I've realized there will never be justice for them. I didn't think I could lose faith in humanity any more than I already had, but after witnessing some things, it feels like the world is a dystopia where victims don't get justice and corruption prevails", Alice Glass explained in a statement. On October 9, 2012, the track listing for the album was revealed via the duo's official Facebook page.
During the question and answer section of the paper, Moniz, it is alleged, "startled" Fulton by inquiring if this procedure might be extended to human subjects suffering from mental illness. Fulton stated that he replied that while possible in theory, it was surely "too formidable" an intervention for use on humans.
Sources: en.wikipedia.org
This period has the only known secure dating in the Kizil Caves: Cave 69 has a painting of a royal Kuchean couple with an inscription in the halo of the King: "Temple Constructed for the Benefit of Suvarnapushpa by His Son", Suvarnapuspa having ruled between 600 and 625, and his three sons died before 647 CE according to Chinese sources. When he visited Kucha in 630 CE, the Chinese monk Xuanzang received the favours of Suvarnadeva, the son and successor of Suvarna-puspa, and Hinayana king of Kucha. Xuanzang described in many details the characteristics of Kucha (屈支国 qūzhīguó, in "大唐西域记" "Tang Dynasty Account of the Western Regions"), and probably visited Kizil: 1) "The style of writing is Indian, with some differences" 2) "They clothe themselves with ornamental garments of silk and embroidery. They cut their hair and wear a flowing covering (over their heads)" 3) "The king is of Kuchean ("屈支" qūzhī) race" 4) "There are about one hundred convents (saṅghārāmas) in this country, with five thousand and more disciples. These belong to the Little Vehicle of the school of the Sarvāstivādas (Shwo-yih-tsai-yu-po). Their doctrine (teaching of Sūtras) and their rules of discipline (principles of the Vinaya) are like those of India, and those who read them use the same (originals)." 5) "About 40 li to the north of this desert city there are two convents close together on the slope of a mountain". These events were soon before the Tang campaign against Kucha in 648 CE.
In nuclear physics, secular equilibrium is a situation in which the quantity of a radioactive isotope remains constant because its production rate (e.g., due to decay of a parent isotope) is equal to its decay rate. An example of this is the germanium-68/gallium-68 generator commonly used for the preparation of gallium-68 radiopharmaceuticals for PET imaging.
=== DNA and gene synthesis === Driven by dramatic decreases in costs of oligonucleotide ("oligos") synthesis and the advent of PCR, the sizes of DNA constructions from oligos have increased to the genomic level. In 2000, researchers reported synthesis of the 9.6 kbp (kilo bp) Hepatitis C virus genome from chemically synthesized 60 to 80-mers. In 2002, researchers at Stony Brook University succeeded in synthesizing the 7741 bp poliovirus genome from its published sequence, producing the second synthetic genome, spanning two years. In 2003, the 5386 bp genome of the bacteriophage Phi X 174 was assembled in about two weeks. In 2006, the same team, at the J. Craig Venter Institute, constructed and patented a synthetic genome of a novel minimal bacterium, Mycoplasma laboratorium and were working on getting it functioning in a living cell. In 2007, it was reported that several companies were offering synthesis of genetic sequences up to 2000 base pairs (bp) long, for a price of about $1 per bp and a turnaround time of less than two weeks. Oligonucleotides harvested from a photolithographic- or inkjet-manufactured DNA chip combined with PCR and DNA mismatch error-correction allows inexpensive large-scale changes of codons in genetic systems to improve gene expression or incorporate novel amino-acids (see George M. Church's and Anthony Forster's synthetic cell projects.). This favors a synthesis-from-scratch approach. Additionally, the CRISPR/Cas system has emerged as a promising technique for gene editing.
Sources: en.wikipedia.org
== Features == Native chemical ligation forms the basis of modern chemical protein synthesis, and has been used to prepare numerous proteins and enzymes by total chemical synthesis. The payoff in the native chemical ligation method is that coupling long peptides by this technique is typically near quantitative and provides synthetic access to large peptides and proteins otherwise impossible to make, due to their large size, decoration by post-translational modification, and containing non-coded amino acid or other chemical building blocks. Native chemical ligation is inherently 'Green' in its atom economy and its use of benign solvents. It involves the reaction of an unprotected peptide thioester with a second, unprotected peptide that has an N-terminal cysteine residue. It is carried out in aqueous solution at neutral pH, usually in 6 M guanidine.hydrochloride, in the presence of an arylthiol catalyst and typically gives near-quantitative yields of the desired ligation product. Peptide-thioesters can be directly prepared by Boc chemistry SPPS; however, thioester-containing peptides are not stable to treatment with a nucleophilic base, thus preventing direct synthesis of peptide thioesters by Fmoc chemistry SPPS. Fmoc chemistry solid phase peptide synthesis techniques for generating peptide-thioesters are based on the synthesis of peptide hydrazides that are converted to peptide thioesters post-synthetically. Polypeptide C-terminal thioesters can also be produced in situ, using so-called N,S-acyl shift systems.
=== Pharmacokinetics === The pharmacokinetics of SR-17018 in rodents have been studied. In mice, it is orally active, showing 69% bioavailability, has an elimination half-life of approximately 6 hours, and efficiently crosses the blood–brain barrier into the central nervous system. The drug has greatly improved bioavailability orally compared to intraperitoneally in mice. Its half-life in mice is longer than that of morphine or oxycodone. Similarly, its duration is longer than that of morphine or fentanyl in mice.
Resilin is a disordered protein; however, its segments may take on secondary structures under different conditions. It is discovered that peptide sequence encoded by exon 1 exhibit an unstructured form and cannot be crystallized, which allows the peptide sequence segment to be very soft and highly flexible. Exon 3 encoded peptide takes on the unstructured form before loading, but transforms to an ordered beta-turn structure once stress is applied. Meanwhile, segment encoded by exon 2 serves as a chitin binding domain. It is proposed that as stress is applied, or there is energy input, exon 1 encoded peptide responds immediately due to its high flexibility. Once this occurs, the energy is passed onto exon 3 encoded peptide, which transforms from the unstructured form to beta-turn structure to store energy. Once the stress or energy is removed, exon 3 encoded segment reverses the structural transformation and outputs the energy to exon 1 encoded segment. Another secondary structure exon 1 and exon 3 corresponding peptides may take on is the polyproline helix (PPII), indicated by the high occurrence of proline and glycine in these 2 segments. The PPII structure widely exists in elastomeric proteins, such as abductin, elastin, and titin. It is believed to contribute in the self-assembling process and the elasticity of the protein. The elastic mechanism of resilin is proposed to be entropy-related. Under relaxed state, the peptide is folded, and possesses a large entropy, but once it is stretched out, the entropy decreases as the peptide unfold.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.